%0 Journal Article %A ANNA ANSCHLAG %A BRANDON H. GREENE %A LORIANNA KÖNNEKER %A MARKUS LUSTER %A JAMES NAGARAJAH %A SABINE WÄCHTER %A ANNETTE WUNDERLICH %A ANDREAS PFESTROFF %T Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells In Vitro %D 2021 %R 10.21873/invivo.12313 %J In Vivo %P 721-729 %V 35 %N 2 %X Background/Aim: We evaluated the potential of the kinase inhibitors sorafenib, lenvatinib and selumetinib on increasing the uptake of technetium-99m into thyroid cancer cells. Materials and Methods: Four established cell lines and three patient’s cell cultures were treated with 0.1, 1 and 5 μM of sorafenib, lenvatinib and selumetinib for 72 hours. After incubation with 1 MBq of technetium-99m, the radioactivity uptake was measured. Results: The experiments showed heterogeneous results. Maximum technetium-99m uptake increases of 312% (sorafenib), 326% (lenvatinib) and 759% (selumetinib) were obtained using the highest applied concentrations. In some tests, an uptake reduction or no effect was observed. Conclusion: Kinase inhibitors have a positive effect on technetium-99m uptake. Due to study limitations, a redifferentiating effect of the drugs could not be definitely proven. Unspecific cytotoxicity might have a confounding effect. %U https://iv.iiarjournals.org/content/invivo/35/2/721.full.pdf